Rare case of primary pleural lymphoma presenting with pleural effusion

Sun, Meiling; Shang, Bin; Gao, Jian-Hua; Jiang, Shujuan

doi:10.1111/1759-7714.12256

Cited by 10 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proposed pathophysiological mechanisms of action are: (a) Direct infiltration of the pleural space; (b) lymphatic obstruction with infiltration of pulmonal and mediastinal lymph nodes and; (c) obstruction of the ductus thoracicus , which leads to the formation of a chylothorax. New studies show that the main mechanisms are infiltration of the pleural space and tumor-host cell interactions [51,52,53].…”

Section: Cancer and Malignant Pleural Effusionmentioning

confidence: 99%

See 1 more Smart Citation

Malignant Pleural Effusion and Its Current Management: A Review

et al. 2019

View full text Add to dashboard Cite

Malignant pleural effusion (MPE) is an exudative effusion with malignant cells. MPE is a common symptom and accompanying manifestation of metastatic disease. It affects up to 15% of all patients with cancer and is the most common in lung, breast cancer, lymphoma, gynecological malignancies and malignant mesothelioma. In the last year, many studies were performed focusing on the pathophysiological mechanisms of MPE. With the advancement in molecular techniques, the importance of tumor-host cell interactions is becoming more apparent. Additionally, the process of pathogenesis is greatly affected by activating mutations of EGFR, KRAS, PIK3CA, BRAF, MET, EML4/ALK and RET, which correlate with an increased incidence of MPE. Considering all these changes, the authors aim to present a literature review of the newest findings, review of the guidelines and pathophysiological novelties in this field. Review of the just recently, after seven years published, practice guidelines, as well as analysis of more than 70 articles from the Pubmed, Medline databases that were almost exclusively published in indexed journals in the last few years, have relevance and contribute to the better understanding of the presented topic. MPE still presents a severe medical condition in patients with advanced malignancy. Recent findings in the field of pathophysiological mechanisms of MPE emphasize the role of molecular factors and mutations in the dynamics of the disease and its prognosis. Treatment guidelines offer a patient-centric approach with the use of new scoring systems, an out of hospital approach and ultrasound. The current guidelines address multiple areas of interest bring novelties in the form of validated prediction tools and can, based on evidence, improve patient outcomes. However, the role of biomarkers in a clinical setting, possible new treatment modalities and certain specific situations still present a challenge for new research.

show abstract

Section: Cancer and Malignant Pleural Effusionmentioning

confidence: 99%

“…Primary lymphoma accounts for 7% of all lymphomas. It occurs in patients with HIV and patients that have pleural empyema, due to active tuberculosis [51,52,54]. The diagnosis of MPE caused by lymphomas is very difficult, mainly because of the scarcity of cells in the effusion [55].…”

Section: Cancer and Malignant Pleural Effusionmentioning

confidence: 99%

Malignant Pleural Effusion and Its Current Management: A Review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…R-CHOP, a multi-drug rituximab-based chemoimmunotherapy regimen, is the standard therapy for DLBCL patients (8). The pathogenesis of primary pleural DLBCL is not yet elucidated and chronic inflammation is considered to be involved (9). According to the report of Iwasa et al (1), we found only seven similar cases documented previously, which were non-pyothoraxassociated primary pleural DLBCL with pleural thickening or masses but without pleural effusion.…”

Section: Discussionmentioning

confidence: 75%

Non-pyothorax-associated primary pleural lymphoma without pleural effusion in an immunocompetent patient: a case report and literature review

Shao

Guo

Xu³

et al. 2018

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“…The clinical manifestations and findings of a pleural effusion analysis reveal characteristics similar to pleural tuberculosis; hence a pleural biopsy is necessary to avoid a misdiagnosis (12). Thoracic surgical resection or thoracoscopic biopsy is sometimes required when CT-guided needle biopsy (a less-invasive procedure) is unsatisfactory for a definite diagnosis of pleural lymphoma (9, 11). DLBCL is the most common type of primary chest wall lymphoma, and destructive invasion into adjacent ribs is sometimes observed, as it was in our case (6).…”

Section: Discussionmentioning

confidence: 99%

Primary Chest Wall MYC/BCL6 Double-hit Lymphoma with t (3;7) (q27;p12) and t (8;14) (q24;q32) Translocations

et al. 2019

View full text Add to dashboard Cite

Primary chest wall lymphoma is rare and typically associated with chronic pleural inflammation. Doublehit lymphoma (DHL), which is defined as aggressive mature B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements, is a highly aggressive malignancy that tends to have extranodal involvement and is resistant to standard immunochemotherapy. We herein report a 55-year-old man with no history of chronic pleural inflammation, diagnosed with primary chest wall DHL with MYC/BCL6 rearrangement, and harboring a unique BCL6 translocation, t(3;7)(q27;p12). After six courses of intensive chemotherapy, he has achieved complete remission. To our knowledge, this is the first case report of primary chest wall DHL.

show abstract

Rare case of primary pleural lymphoma presenting with pleural effusion

Cited by 10 publications

References 31 publications

Malignant Pleural Effusion and Its Current Management: A Review

Malignant Pleural Effusion and Its Current Management: A Review

Non-pyothorax-associated primary pleural lymphoma without pleural effusion in an immunocompetent patient: a case report and literature review

Primary Chest Wall MYC/BCL6 Double-hit Lymphoma with t (3;7) (q27;p12) and t (8;14) (q24;q32) Translocations

Contact Info

Product

Resources

About